Drug intelligence / Profile preview

RV-1780

Development stage: Preclinical
Lead developer: RNAimmune
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**RV-1780** is an RNAimmune investigational **mRNA vaccine** program for an undisclosed infectious disease. RNAimmune has described it in its pipeline as an mRNA combination vaccine in the IND-enabling stage. The encoded antigen composition, pathogen target, delivery formulation, route of administration, and detailed mechanism have not been publicly disclosed.

Beyond the preview

Go deeper on RV-1780.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV-1780.

Explore the full profile